Full Text View
Tabular View
No Study Results Posted
Related Studies
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
This study is ongoing, but not recruiting participants.
First Received: November 12, 2002   Last Updated: May 9, 2009   History of Changes
Sponsors and Collaborators: Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00049452
  Purpose

RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in preventing bone loss in premenopausal women who are receiving chemotherapy after surgery for early stage breast cancer.


Condition Intervention Phase
Breast Cancer
Osteoporosis
 Drug: zoledronic acid
 Phase III

Study Type: Interventional
Study Design: Supportive Care, Randomized, Double-Blind, Placebo Control
Official Title: A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer Osteoporosis Surgery
Drug Information available for: Zoledronic acid
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Changes in lumbar spine bone mineral density (BMD) at 6 months

Secondary Outcome Measures:
  • Changes in lumbar spine BMD at 12 and 24 months
  • Total hip and femoral neck BMD at 6, 12, and 24 months
  • Serum markers of bone turnover (osteocalcin, bone-specific alkaline phosphatase, and cross-linked C-telopeptide of type 1 collagen levels) measured every 6 weeks for 6 months, and at 9 and 12 months
  • Quality of life as measured by the Short Form-36 instrument at baseline, and at 6 and 12 months
  • Treatment costs

Estimated Enrollment: 120
Study Start Date: December 2001
Detailed Description:

OBJECTIVES:

  • Compare the changes in bone mineral density (BMD) and bone turnover that occur in premenopausal women with resected early stage breast cancer during and after 6 months of adjuvant chemotherapy.
  • Determine the factors that predict bone loss during chemotherapy, particularly induction of amenorrhea, type of chemotherapeutic regimen, glucocorticoid exposure, and baseline BMD, in these patients.
  • Determine whether zoledronate prevents bone loss in these patients when given during and after adjuvant chemotherapy.
  • Determine the effect of zoledronate on markers of bone turnover in these patients during and after adjuvant chemotherapy.
  • Determine whether the effect on markers of bone turnover predicts response to zoledronate in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to estrogen receptor status (positive vs negative), progesterone receptor status (positive vs negative), and adjuvant chemotherapy regimen. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive zoledronate IV over 15 minutes on day 1.
  • Arm II: Patients receive placebo IV over 15 minutes on day 1. In both arms, treatment repeats every 3 months for up to 4 courses in the absence of disease progression. Patients also receive calcium and cholecalciferol (vitamin D) supplements daily.

Quality of life is assessed at baseline and at 6 and 12 months.

Patients are followed at 1 year.

PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of localized breast cancer

    • Stage I or II (T1-3, N0-2, M0)
  • Planned adjuvant chemotherapy (after surgery) of at least 6 months in duration

  • Hormone receptor status:

    • Estrogen receptor and progesterone receptor status known

PATIENT CHARACTERISTICS:

Age

  • 18 to 50

Sex

  • Female

Menopausal status

  • Premenopausal or perimenopausal

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Creatinine less than 2 mg/dL

Other

  • No T score of less than 2.0 on bone mineral density (BMD)
  • No fragility fracture
  • No lumbar spine anatomy that would preclude accurate BMD measurement of a minimum of 3 lumbar vertebrae
  • Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • Not specified

Radiotherapy

  • No concurrent radiotherapy

Surgery

  • See Disease Characteristics

Other

  • At least 1 month since prior calcitonin
  • At least 12 months since prior bisphosphonates given for more than 1 month duration
  • No concurrent fluoride therapy (10 mg/day or more)
  • No concurrent enrollment in another experimental drug study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00049452

Locations
United States, Connecticut
Carl and Dorothy Bennett Cancer Center at Stamford Hospital
Stamford, Connecticut, United States, 06904
United States, New Jersey
Valley Hospital - Paramus
Paramus, New Jersey, United States, 07652-2509
United States, New York
Herbert Irving Comprehensive Cancer Center at Columbia University
New York, New York, United States, 10032
Sponsors and Collaborators
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Study Chair: Dawn Hershman, MD Herbert Irving Comprehensive Cancer Center
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications:
Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008 Oct 10;26(29):4739-45. Epub 2008 Aug 18.

Study ID Numbers: CDR0000258105, CPMC-IRB-14069, NCI-G02-2127, NOVARTIS-CPMC-IRB-14069
Study First Received: November 12, 2002
Last Updated: May 9, 2009
ClinicalTrials.gov Identifier: NCT00049452     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
osteoporosis
stage I breast cancer
stage II breast cancer

Study placed in the following topic categories:
Zoledronic acid
Musculoskeletal Diseases
Skin Diseases
Osteoporosis
Breast Neoplasms
 Bone Density Conservation Agents
Bone Diseases, Metabolic
Bone Diseases
Breast Diseases

Additional relevant MeSH terms:
Zoledronic acid
Skin Diseases
Physiological Effects of Drugs
Breast Neoplasms
Osteoporosis
Bone Diseases, Metabolic
Bone Density Conservation Agents
 Bone Diseases
Pharmacologic Actions
Neoplasms
Neoplasms by Site
Musculoskeletal Diseases
Breast Diseases

ClinicalTrials.gov processed this record on July 02, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services